Zentalis

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing clinically differentiated, novel small-molecule therapies targeting fundamental biological pathways of cancer. In addition to its lead program, ZN-c5 (an oral SERD for estrogen receptor-positive, HER2-negative breast cancer), the company is advancing a broad pipeline of oncology candidates to address areas of significant unmet medical need. The company has offices in New York and San Diego.